quinazolines has been researched along with idelalisib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, M; Frenzel, LP; Göckeritz, E; Hallek, M; Kerwien, S; Klein, C; Krause, G; Landwehr, T; Liu, N; Neumann, L; Vondey, V; Wendtner, CM; Wigger, M | 1 |
| Feiz Barazandeh, A; Jia, P; Keynan, Y; Khadem, F; Liu, D; Mou, Z; Uzonna, JE | 1 |
| Janku, F; Meric-Bernstam, F; Yap, TA | 1 |
| Duan, W; Feng, Y; Hei, YY; Mao, S; Shen, Y; Xin, M; Zhang, H; Zhang, SQ; Zhao, HY | 1 |
| Hallek, M; Hassenrück, F; Krause, G | 1 |
| Ahmed, J; Aksoy, E; Alusi, G; Burns, E; Chard Dunmall, LS; Ferguson, MS; Gangeswaran, R; Hiley, C; Lemoine, NR; Marelli, G; Tysome, JR; Vanhaesebroeck, B; Wang, Y; Whitehead, MA | 1 |
| Dittakavi, S; Kumar, R; Mullangi, R; Siddesh, A; Sriram, D; Trivedi, RK; Zainuddin, M; Zakkula, A | 1 |
| Adib, D; Gupta, D; Mamlouk, K; Nellesen, D; Proudman, D; Yang, J | 1 |
3 review(s) available for quinazolines and idelalisib
| Article | Year |
|---|---|
Targeting the PI3K pathway in cancer: are we making headway?
Topics: Class I Phosphatidylinositol 3-Kinases; Everolimus; Humans; Molecular Targeted Therapy; Neoplasms; Oncogene Protein v-akt; Purines; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Topics: Animals; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones | 2018 |
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-
Topics: Benzamides; Biphenyl Compounds; Child, Preschool; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Lymphoma, Follicular; Morpholines; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Purines; Pyridones; Pyrimidines; Quinazolines; Quinazolinones; Risk | 2022 |
5 other study(ies) available for quinazolines and idelalisib
| Article | Year |
|---|---|
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Isoenzymes; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones; Rituximab; Signal Transduction | 2015 |
Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.
Topics: Adenine; Amphotericin B; Animals; CD4 Lymphocyte Count; Class I Phosphatidylinositol 3-Kinases; Cytokines; Drug Therapy, Combination; Female; Immunomodulation; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liver; Lymph Nodes; Mice; Mice, Inbred BALB C; Parasite Load; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolines; Quinazolinones; Spleen; T-Lymphocytes, Regulatory | 2017 |
Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Design; Half-Life; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Purines; Quinazolines; Quinazolinones; Rats; Structure-Activity Relationship | 2018 |
Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Topics: Adenine; Administration, Intravenous; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Female; Immunotherapy; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Oncolytic Viruses; Purines; Quinazolines; Quinazolinones; Transplantation, Homologous; Treatment Outcome; Tumor Burden; Vaccinia virus | 2020 |
Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Isoquinolines; Linear Models; Liquid-Liquid Extraction; Male; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity | 2021 |